\nMasimo Corporation (\u201cMasimo\u201d or the \u201cCompany\u201d) (Nasdaq: MASI) today announced that Joe Kiani, founder, Chairman and Chief Executive Officer of Masimo, unconditionally, irrevocably and permanently waived his right to assert that a Change in Control has occurred pursuant to Section 9(iii) of his employment agreement unless there occurs a change in the Company\u2019s Board in which the individuals who constituted the Board at the beginning of the twelve (12) month period immediately preceding the change cease for any reason to constitute one-half or more of the directors then in office. The full text of the waiver has been filed with the U.S. Securities and Exchange Commission. Mr. Kiani previously waived his rights to assert that a Change in Control has occurred as a result of the election of stockholder-nominated directors at the 2023 annual meeting of stockholders, and that the appointment of any lead independent director of the Board constitutes Good Reason under his employment agreement.<\/p>\n
\n\u201cI have waived these rights because I believe strongly that they should not be factors in this pivotal vote on the future of Masimo,\u201d said Mr. Kiani. \u201cBy permanently putting these issues to rest, I hope stockholders can focus on the stark choice they have between Masimo\u2019s proven track record and bright future and Quentin Koffey\u2019s dangerous and ill-informed agenda.\u201d<\/p>\n
\nTo protect stockholders\u2019 investment and to ensure Masimo continues to create value, the Board encourages stockholders to vote FOR Masimo\u2019s highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D.<\/p>\n
\nFind more information on why your vote is so important to the future of Masimo at www.KeepMasimoStrong.com<\/a>.<\/p>\n About Masimo<\/b><\/p>\n \nMasimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins\u00ae<\/sup>, Denon\u00ae<\/sup>, Marantz\u00ae<\/sup>, and Polk Audio\u00ae<\/sup>. Our mission is to improve life, improve patient outcomes and reduce the cost of care. Masimo SET\u00ae<\/sup> Measure-through Motion and Low Perfusion\u2122<\/sup> pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET\u00ae<\/sup> has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet\u2122<\/sup> in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET\u00ae<\/sup> is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll. In 2005, Masimo introduced rainbow\u00ae<\/sup> Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb\u00ae<\/sup>), oxygen content (SpOC\u2122<\/sup>), carboxyhemoglobin (SpCO\u00ae<\/sup>), methemoglobin (SpMet\u00ae<\/sup>), Pleth Variability Index (PVi\u00ae<\/sup>), RPVi\u2122<\/sup> (rainbow\u00ae<\/sup> PVi), and Oxygen Reserve Index (ORi\u2122<\/sup>). In 2013, Masimo introduced the Root\u00ae<\/sup> Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine\u00ae<\/sup> Brain Function Monitoring, O3\u00ae<\/sup> Regional Oximetry, and ISA\u2122<\/sup> Capnography with NomoLine\u00ae<\/sup> sampling lines. Masimo\u2019s family of continuous and spot-check monitoring Pulse CO-Oximeters\u00ae<\/sup> includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7\u00ae<\/sup>, Radius PPG\u00ae<\/sup> and Radius VSM\u2122<\/sup>, portable devices like Rad-67\u00ae<\/sup>, fingertip pulse oximeters like MightySat\u00ae<\/sup> Rx, and devices available for use both in the hospital and at home, such as Rad-97\u00ae<\/sup>. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation\u2122<\/sup> platform, and include Iris\u00ae<\/sup> Gateway, iSirona\u2122, Patient SafetyNet, Replica\u00ae<\/sup>, Halo ION\u00ae<\/sup>, UniView\u00ae<\/sup>, UniView :60\u2122<\/sup>, and Masimo SafetyNet\u00ae<\/sup>. Its growing portfolio of health and wellness solutions includes Radius T\u00ae<\/sup> and Masimo W1\u2122 <\/sup>watch. Additional information about Masimo and its products may be found at www.masimo.com<\/a>. Published clinical studies on Masimo products can be found at www.masimo.com\/evidence\/featured-studies\/feature\/<\/a>.<\/p>\n \nORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nAll statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, certain statements regarding Politan Capital and its founder, Quentin Koffey, including Mr. Koffey\u2019s dangerous and ill-informed agenda for Masimo, and the impact of Mr. Kiani\u2019s irrevocable and permanent waivers under his employment agreement with Masimo. These forward-looking statements are based on management\u2019s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include those set forth in this press release and certain other factors discussed in the \u201cRisk Factors\u201d section of our most recent periodic reports filed with the Securities and Exchange Commission (\u201cSEC\u201d), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC\u2019s website at www.sec.gov<\/a>. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.<\/p>\n Additional Information Regarding The Annual Meeting of Stockholders Currently Expected to Be Held on June 26, 2023 and Where to Find It<\/b><\/p>\n \nMasimo has filed a definitive proxy statement containing a form of WHITE proxy card with the SEC in connection with its solicitation of proxies for its 2023 Annual Meeting. MASIMO\u2019S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT (AND ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ACCOMPANYING WHITE PROXY CARD AS THEY WILL CONTAIN OR CONTAIN IMPORTANT INFORMATION. Shareholders may obtain the proxy statement, any amendments or supplements to the proxy statement and other documents as and when filed by Masimo with the SEC without charge from the SEC\u2019s website at www.sec.gov<\/a>.<\/p>\n Certain Information Regarding Participants<\/b><\/p>\n \nMasimo, its directors and certain of its executive officers may be deemed to be participants in connection with the solicitation of proxies from Masimo\u2019s shareholders in connection with the matters to be considered at the 2023 Annual Meeting. Information regarding the ownership of Masimo\u2019s directors and executive officers in Masimo common shares is included in Masimo\u2019s definitive proxy statement, which can be found through the SEC\u2019s website at www.sec.gov<\/a>. To the extent holdings of Masimo\u2019s securities by directors or executive officers have changed since the amounts set forth in the definitive proxy statement, such changes have been or will be reflected on SEC filings filed by the applicable individuals on Forms 3, 4, and 5, which can be found through the SEC\u2019s website at www.sec.gov<\/a>. These documents can be obtained free of charge from the sources indicated above.<\/p>\n Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are <\/i>trademarks or registered trademarks of Masimo Corporation.<\/i><\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230606005589\/en\/<\/a><\/span><\/p>\n Investor Contact: Eli Kammerman Media Contact: Evan Lamb KEYWORDS:<\/b> United States North America California<\/p>\n INDUSTRY KEYWORDS:<\/b> Hospitals Health Technology Health Medical Devices<\/p>\n<\/p>\n
\n<\/b>
(949) 297-7077
\n
ekammerman@masimo.com<\/a><\/p>\n
\n<\/b>
(949) 396-3376
\n
elamb@masimo.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230606005589\/en\/1811895\/3\/Masimo_Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n